3rd Annual Innate Killer Summit
Organiser Name: Hanson Wade Ltd.
Contact: Georgina FitzGerald
georgina.fitzgerald@hansonwade.com
+4402031418706
As the cell immunotherapy field continues to explode beyond the well-hyped CAR-Ts, the Innate Killer Summit 2018 gathers the leading scientific and business experts from all the key stakeholders to identify future approaches to deliver commercially viable off-the-shelf therapies.
By harnessing the unique power of the innate immune system, seize the enhanced drug development opportunity of NK cell immunotherapies. Capitalize on a more robust allogeneic development approach that overcomes common safety concerns experienced by other cell therapies.
The 3rd Innate Killer Summit offers the platform for experts and leaders in the Innate Killer Community to come together, network and create collaborative partnerships.
Learn from case studies on:
Increasing Persistency and Specificity with CAR-NK – novel clinical data outlining methods to redirect NK
cell specificity and in vivo persistence
Combination Therapies to Support and Enhance Immunotherapeutic Response – explore the use of targeted antibodies and cytokines to work alongside NK cells to improve their role in persistence and anti-tumor effects
Off-the-Shelf Allogeneic Therapies to Improve Accessibility of Treatment – utilize the capability of administering NK therapies as an “Off-the-Shelf” living drug
Manufacturing Considerations to Improve Proliferation in NK Clinical Trials – create solutions to manufacturing hurdles specifically in regards to scaling up, expansion and increasing NK proliferative capabilities
Regulatory Outline to Ensure Safety and Efficacy in NK Clinical Trials – identify the regulatory framework and procedures that surround NK research area
